KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Debt to Equity (2020 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Debt to Equity for 7 consecutive years, with $0.06 as the latest value for Q1 2026.

  • For Q1 2026, Debt to Equity fell 6.41% year-over-year to $0.06; the TTM value through Mar 2026 reached $0.06, down 6.41%, while the annual FY2025 figure was $0.06, 6.01% down from the prior year.
  • Debt to Equity hit $0.06 in Q1 2026 for Regeneron Pharmaceuticals, down from $0.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.1 in Q1 2022 and bottomed at $0.06 in Q1 2026.
  • Average Debt to Equity over 5 years is $0.08, with a median of $0.07 recorded in 2024.
  • Year-over-year, Debt to Equity plummeted 39.81% in 2022 and then fell 5.2% in 2025.
  • Regeneron Pharmaceuticals' Debt to Equity stood at $0.09 in 2022, then dropped by 12.67% to $0.08 in 2023, then dropped by 11.45% to $0.07 in 2024, then dropped by 6.01% to $0.06 in 2025, then fell by 0.52% to $0.06 in 2026.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.06, $0.06, and $0.06 for Q1 2026, Q4 2025, and Q3 2025 respectively.